Physician profile
John R Sweeney
NPI 1790788065
$4,498.34
in general payments reported to CMS, 2019-2025
26 companies · $112 in 2025
The $112 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $990 · 2020: $723 · 2021: $1,370 · 2022: $842 · 2023: $175 · 2024: $286 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $573.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $573.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,078.06 | 2019-2025 | Airsupra |
| Glaxosmithkline, LLC. | $633.23 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $319.38 | 2019-2022 | |
| Optinose US, INC. | $293.28 | 2019-2021 | |
| Grifols USA, LLC | $204.41 | 2019-2022 | |
| Kaleo, INC. | $202.40 | 2019-2022 | |
| Genzyme Corporation | $194.15 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $192.93 | 2023-2024 | Zoryve, Seglentis |
| Amgen INC. | $180.55 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $180.02 | 2022-2023 | |
| Biocryst US Sales Co., LLC | $166.69 | 2021-2022 | |
| Genentech USA, INC. | $153.31 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.66 | 2020-2022 | |
| Csl Behring | $97.58 | 2020-2021 | |
| Abbvie INC. | $95.40 | 2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $90.60 | 2019-2021 | |
| Lilly USA, LLC | $89.94 | 2024 | Zepbound |
| Teva Pharmaceuticals USA, INC. | $41.69 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.99 | 2021-2022 | |
| Pharming Healthcare, INC. | $35.12 | 2019-2022 | |
| Octapharma USA, INC. | $25.12 | 2021 | |
| Novartis Pharmaceuticals Corporation | $25.00 | 2020 | |
| Biocryst Pharmaceuticals, INC. | $18.64 | 2020 | |
| Shionogi INC | $16.95 | 2019 | |
| Merck Sharp & Dohme LLC | $16.62 | 2021 | |
| Shire North American Group INC | $11.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Sweeney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.